Peptide Nucleic Acids: A Gene-Silencing Strategy to Fight Antibiotic-Resistant Bacteria | Research

The takeaway

Peptide nucleic acids (PNAs) can selectively silence essential bacterial genes to combat multidrug-resistant pathogens while sparing beneficial gut bacteria.

Species-specific
PNAs can be programmed to kill targeted resistant bacteria while sparing beneficial microbiota

What the researchers found

PNAs demonstrate species-specific antimicrobial activity through targeted gene silencing, with recent delivery advances (cell-penetrating peptides, dendron conjugates, nanoparticles) significantly improving their therapeutic potential.

Why it matters

Antimicrobial resistance is a global health crisis. PNAs offer a fundamentally different approach—targeting genes rather than proteins—that could be customized to fight specific resistant bacteria without contributing to broader resistance.

How the study worked

Narrative review of in vitro and in vivo studies on PNA-based antimicrobial strategies, including delivery platform development and combination therapy approaches.

What this study cannot tell us

Most evidence is from in vitro studies; in vivo data remain limited. Delivery to bacterial cells inside the body remains challenging. Large-scale production is costly. Clinical trials are needed.

How to read the evidence

Narrative review of an emerging technology with mostly in vitro evidence and limited in vivo data. Promising concept at early development stage.

When this study was published

Published in 2025, reflecting the current state of PNA antimicrobial development.

The bigger picture

PNAs sit at the intersection of peptide chemistry and genetic medicine. Their programmable, species-specific design represents a precision antimicrobial approach that could complement or eventually replace broad-spectrum antibiotics.

Questions still open

Can PNA-based antimicrobials achieve sufficient tissue concentrations for treating deep-seated infections?
How quickly might bacteria develop resistance to PNA gene-silencing approaches?
Will manufacturing costs decrease enough for PNAs to be practical clinical therapeutics?

Common questions

What are peptide nucleic acids and how do they fight bacteria?

PNAs are synthetic molecules with peptide-like structures that can bind to specific bacterial RNA. By blocking the production of essential proteins, they effectively shut down targeted bacteria without affecting other species.

Could PNAs replace antibiotics?

PNAs could complement antibiotics, especially against drug-resistant bacteria. Their ability to be programmed for specific species and combined with conventional drugs makes them a promising addition to the antimicrobial toolkit, though clinical development is still in early stages.

Read the original research

Peptide Nucleic Acids (PNAs) in Antimicrobial Therapy: A Next Generation Strategy.

International journal of molecular sciences, 27(3)

View on PubMed ↗Publisher’s paper ↗

Citation

D'Aniello, Antonia; Masi, Annalisa; Avitabile, Concetta; Del Monaco, Giovanni; Saviano, Michele; Moccia, Maria. (2026). Peptide Nucleic Acids (PNAs) in Antimicrobial Therapy: A Next Generation Strategy.. International journal of molecular sciences, 27(3). https://doi.org/10.3390/ijms27031565